002653:SZSEHaisco Pharmaceutical Group Co. Ltd. Class A Analysis
Data as of 2026-08-29 - not real-time
CN¥67.18
Latest Price
6/10Risk
Risk Level: Medium
Executive Summary
Haisco Pharmaceutical Group Co., Ltd. trades at ¥67.18, with its short-term moving averages stacked above the longer-term ones — a bullish trend structure. It has lost 5.7% over the past 30 days. With RSI at 51.1 the momentum picture is neutral, alongside a bearish MACD signal. Recent trading has carved out support near ¥58.79 and resistance around ¥74.22.
Multiples put this in overvalued territory: 79.0 times earnings against the sector's 30.5. Analyst price targets sit 44.2% above the current price. Revenue is growing at 38.1% on a 17.3% profit margin. The 1.18% dividend yield looks covered by current payout levels.
On a 1-10 scale the risk profile lands at 6 — elevated. With 30-day volatility of 55.5%, a beta of 0.32 and a maximum drawdown of 30.2%, position sizing matters here. The wider market backdrop reads extreme greed at 96 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 3 out of 10.
Multiples put this in overvalued territory: 79.0 times earnings against the sector's 30.5. Analyst price targets sit 44.2% above the current price. Revenue is growing at 38.1% on a 17.3% profit margin. The 1.18% dividend yield looks covered by current payout levels.
On a 1-10 scale the risk profile lands at 6 — elevated. With 30-day volatility of 55.5%, a beta of 0.32 and a maximum drawdown of 30.2%, position sizing matters here. The wider market backdrop reads extreme greed at 96 on the fear-greed composite.
Across every horizon the signals point the same way: hold, at a conviction of 3 out of 10.
Top Market Events
On April 10, 2026, Haisco Pharmaceutical Group Co.Haisco Announces Licensing And Research Collaboration Agreement With Lilly To Develop Innovative Medicines Across...On June 23, 2026 Beijing time , Haisco Pharmaceutical Group Co.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 3/10
Key Factors
- Short-term moving averages stacked above long-term ones
- Trading above the 200-day average of 56.34
- MACD momentum is negative
Medium Term
1–3 yearsNeutral
Model confidence: 3/10
Key Factors
- Short-term moving averages stacked above long-term ones
- P/E of 79.0 versus sector average of 30.5
- Trading above the 200-day average of 56.34
Long Term
> 3 yearsNeutral
Model confidence: 3/10
Key Factors
- P/E of 79.0 versus sector average of 30.5
- Analyst targets imply +44.2% versus the current price
- Profit margin of 17.3% is healthy
Key Metrics & Analysis
Financial Health
Revenue Growth38.10%
Profit Margin17.32%
P/E Ratio79.0
ROE21.39%
ROA7.00%
Debt/Equity47.03
P/B Ratio15.8
Op. Cash FlowCN¥1.2B
Free Cash FlowCN¥673.5M
Industry P/E30.5
Technical Analysis
TrendBullish
RSI51.1
SupportCN¥58.79
ResistanceCN¥74.22
MA 20CN¥67.03
MA 50CN¥66.86
MA 200CN¥56.34
MACDBearish
VolumeDecreasing
Fear & Greed Index95.66
Valuation
Fair ValueCN¥20.43
Target PriceCN¥96.89
Upside/Downside44.22%
GradeOvervalued
TypeGrowth
Dividend Yield1.18%
Risk Assessment
Beta0.32
Volatility55.54%
Sector RiskMedium
Reg. RiskHigh
Geo RiskHigh
Currency RiskHigh
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.